Stock Market News
Indivior files Canadian submission for opium use disorder treatment
(WebFG News) - Indivior has filed a new drug submission (NDS) with Health Canada's Therapeutic Drugs Directorate, it announced on Friday, for its 'SUBLOCADE' (buprenorphine extended-release) injection, for subcutaneous use for the treatment of moderate-to-severe opioid use disorder (OUD), as part of a complete treatment plan to include counseling and psychosocial support.
The FTSE 250 drugmaker said Health Canada had granted Priority Review status for SUBLOCADE on 6 April, and if approved, the treatment would be marketed by Indivior Canada.
"The Priority Review designation is an important acknowledgment by Health Canada of the potential for SUBLOCADE to help address the current unmet needs for patients living with opioid use disorder," said Indivior chief executive Shaun Thaxter.
"Indivior looks forward to working closely with regulatory authorities to ensure SUBLOCADE, if approved, will be available as soon as possible to the Canadian treatment community to help address the current opioid public health crisis."
In granting the Priority Review status for the SUBLOCADE NDS, Health Canada noted that opium use disorder was a serious, potentially life-threatening disorder, and that there was substantial evidence of the clinical efficacy of SUBLOCADE in the treatment of moderate to severe cases.
Health Canada also acknowledged that SUBLOCADE had the potential to yield improved efficacy through enhanced adherence, due to its monthly administration, the Indivior board noted.
"A Priority Review designation indicates Health Canada's goal to review the NDS within a shortened target of 180 calendar days," the Indivior board explained.
"Priority Review designation may be granted to drug submissions intended for the treatment, prevention or diagnosis of serious, life-threatening or severely debilitating diseases or conditions for which there is substantial evidence that the overall benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately managed by a drug marketed in Canada."
The NDS submission of SUBLOCADE to Health Canada followed approval of the drug by the US Food and Drug Administration (FDA) on 30 November last year.
The FTSE 250 drugmaker said Health Canada had granted Priority Review status for SUBLOCADE on 6 April, and if approved, the treatment would be marketed by Indivior Canada.
"The Priority Review designation is an important acknowledgment by Health Canada of the potential for SUBLOCADE to help address the current unmet needs for patients living with opioid use disorder," said Indivior chief executive Shaun Thaxter.
"Indivior looks forward to working closely with regulatory authorities to ensure SUBLOCADE, if approved, will be available as soon as possible to the Canadian treatment community to help address the current opioid public health crisis."
In granting the Priority Review status for the SUBLOCADE NDS, Health Canada noted that opium use disorder was a serious, potentially life-threatening disorder, and that there was substantial evidence of the clinical efficacy of SUBLOCADE in the treatment of moderate to severe cases.
Health Canada also acknowledged that SUBLOCADE had the potential to yield improved efficacy through enhanced adherence, due to its monthly administration, the Indivior board noted.
"A Priority Review designation indicates Health Canada's goal to review the NDS within a shortened target of 180 calendar days," the Indivior board explained.
"Priority Review designation may be granted to drug submissions intended for the treatment, prevention or diagnosis of serious, life-threatening or severely debilitating diseases or conditions for which there is substantial evidence that the overall benefit/risk profile is improved over existing therapies, preventatives or diagnostic agents for a disease or condition that is not adequately managed by a drug marketed in Canada."
The NDS submission of SUBLOCADE to Health Canada followed approval of the drug by the US Food and Drug Administration (FDA) on 30 November last year.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price